logo
Paradromics implants brain-computer interface into first human patient

Paradromics implants brain-computer interface into first human patient

UPI2 days ago

Paradromics, a competitor of Neuralink, announced Monday it safely implanted a brain-computer interface into a human patient last month at the University of Michigan, and recorded neural activity before removing it 10 minutes later. Photo by University of Michigan
June 2 (UPI) -- Paradromics, a competitor of Neuralink, announced Monday it safely implanted a brain-computer interface into a human patient and recorded neural activity, before removing it 10 minutes later.
The surgical procedure, performed May 14 at the University of Michigan, marks the first time Paradromics has temporarily implanted its device -- called Connexus -- into a human with the goal of restoring neural signals in patients with spinal cord injuries, stroke or ALS. Until last month, the Austin-based startup had only implanted and tested the device on sheep.
"We've shown in sheep that our device is best in class from a data and longevity standpoint, and now we've also shown that it's compatible with humans," Matt Angle, Paradromics founder and chief executive officer, told CNBC.
Last year, Elon Musk's Neuralink became the first to implant a brain-computer interface into a human patient. Noland Arbaugh, who was paralyzed in an accident in 2016, received "the Link" implant in January 2024. Since then, Arbaugh has been using it for up to eight hours a day and is able to do a variety of digital tasks.
Brain-computer interface companies Precision Neuroscience and Synchron, which is backed by Jeff Bezos and Bill Gates, have also implanted their systems into humans. While brain-computer interfaces interpret neural signals associated with movement, they do not read thoughts.
Connexus, which is smaller than a dime and has 420 small electrodes, is embedded directly into the surrounding brain tissue. Paradromics' BCI records brain activity at the level of individual neurons.
"By having proximity to the individual neurons, you can get the highest-quality signal," said Angle.
The patient, who received last month's Connexus implant, was already undergoing neurosurgery to treat epilepsy and consented to the research, allowing doctors to temporarily implant the device into their temporal lobe.
"There's a very unique opportunity when someone is undergoing a major neurosurgical procedure," said Angle. "They're going to have their skull opened up, and there's going to be a piece of brain that will be imminently removed. Under these conditions, the marginal risk of testing out a brain implant is actually very low."
While Paradromics' Connexus implant is still being reviewed by regulators, research institutions such as the University of Michigan are allowed to use the devices as long as they prove there is no significant risk to the patient.
"You do all of these steps, you validate the hardware, you have this really high degree of rational certainty that things are going to work," Angle said, "but still emotionally when it works and when it happens the way you expected it to, it's still very, very gratifying."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco
Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco

Business Upturn

time26 minutes ago

  • Business Upturn

Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — Sutter Health today broke ground on the new Sutter Advanced Neuroscience Complex at Mission Bernal – a major milestone in expanding access to high-quality neurological and neurosurgical care in Northern California. The five-story, 129,000-square-foot facility will be located at the corner of César Chávez and Valencia streets (3555 César Chavez Street) in San Francisco and is expected to open in 2028. Designed as a regional destination for brain health, the complex will unite care delivery, advanced diagnostics and research in one location. 'Sutter Health has a bold vision for brain health, and that vision includes building a state-of-the-art advanced neuroscience complex in San Francisco,' said Sutter Health President and CEO Warner Thomas. 'CPMC has cared for this community since the 1850s, and we're proud to continue that legacy by investing in a destination for neurological care that will serve patients and families locally and across the region. Our mission drives us to deliver accessible, high-quality care that fuels innovation and expands access so that more people can benefit from the highest standards of neurological health closer to home.' 'San Francisco is leading the nation in providing cutting-edge health care, and this project will bring exceptional neurological care to the heart of our city and better health outcomes for our residents,' said Mayor Daniel Lurie. 'Thank you to Sutter Health for their commitment to our city, to our residents, and to the Mission District. Together, we're building stronger, healthier communities and strengthening San Francisco's comeback.' High-Tech Hub for Brain Health This $442 million investment underscores Sutter Health's long-term commitment to expanding access to specialized, high-acuity care in San Francisco and the broader Bay Area. When complete, the Sutter Advanced Neuroscience Complex at Mission Bernal will bring together approximately 80 physicians and clinicians across range of neurological specialties – including Alzheimer's disease and dementia, ALS, headache, neurosurgery, neurology, epilepsy, neuro-oncology and movement disorders – to deliver seamless, integrated care in one location. The new complex will house a full spectrum of services, including neurology, neurosurgery, imaging, lab, infusion, rehabilitation and an on-site ambulatory surgery center. Patients will also benefit from direct access to leading research and clinical trials, further supporting advancements in diagnosis and treatment. Two of Sutter's nationally recognized programs – the Ray Dolby Brain Health Center and the Forbes Norris MDA/ALS Research and Treatment Center – will relocate to the new complex, enabling greater capacity and deeper collaboration among specialists. The site will also include underground parking to improve convenience for patients and visitors. In a related investment, Sutter plans to add two neurological intervention suites to the adjacent CPMC Mission Bernal campus hospital by 2027. These suites will offer advanced imaging and enable rapid detection and minimally invasive treatment of life-threatening neurological conditions. 'Our goal is to provide coordinated, comprehensive access to integrated care that merges the expertise of neurologists and neurosurgeons,' said Dr. Lewis Leng, a neurosurgeon with Sutter West Bay Medical Group. 'The new Sutter Advanced Neuroscience Complex at Mission Bernal will create more access to care for patients with neurological conditions and provide them the opportunity to take advantage of Sutter's award-winning neuroscience treatment and clinical research.' Christina Oh, president of Sutter's Greater San Francisco Division, added, 'Patients will be able to come to this location and visit their specialist, receive diagnostic lab and imaging, as well as outpatient procedures all in one complex. Having all these services under one roof will create a more convenient, coordinated experience.' The Sutter Advanced Neuroscience Complex is part of Sutter Health's broader strategy to invest nearly $1 billion in healthcare infrastructure across San Francisco over the next five years. This initiative aims to significantly expand access to specialized medical care, such as Sutter's new Otolaryngology-Head and Neck Surgery program, and enhance the overall patient experience. A Vision for Advanced Care and Clinical Training The Mission Bernal Care Complex is part of a larger effort by Sutter Health to address the growing healthcare needs of Northern California, with more than two dozen new facilities currently in development. Beyond expanding access, this complex reflects Sutter's strong commitment to education and workforce development, with plans to train over 1,000 medical residents and fellows by 2030. Sutter CPMC plays a key role in this effort, currently training residents and fellows in nationally accredited Graduate Medical Education programs across a wide range of specialties, including advanced heart failure and transplant cardiology, cardiovascular disease, internal medicine, gastroenterology, hand surgery, hematology-oncology, ophthalmology, pulmonary and critical care medicine, psychiatry and transplant hepatology. CPMC also offers additional training in neurocritical care, among other areas. 'This groundbreaking represents a pivotal moment in advancing Sutter Health's mission to provide high-quality, compassionate and innovative care,' said Ken McNeely, chair of the Sutter Health Board of Directors. 'It reflects our dedication to meeting the evolving healthcare needs of our community while preparing the next generation of physicians and care teams to carry that mission forward.' For more information about the Sutter Advanced Neuroscience Complex at Mission Bernal and Sutter Health's ongoing commitment to healthcare excellence, please visit About Sutter Health Sutter Health is a not-for-profit health care system dedicated to providing comprehensive care throughout California. Committed to community partnerships and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent health care more connected and accessible. Sutter Health currently serves nearly 3.5 million patients, thanks to a dedicated team of more than 57,000 employees and clinicians and 12,000+ affiliated physicians, with a unified focus on expanding care to serve more patients. Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming health care, at Sutter Health, getting better never stops. Learn more about how Sutter Health is transforming health care at and Attachments Artist rendering: Sutter Advanced Neuroscience Complex in San Francisco Groundbreaking for Sutter Advanced Neuroscience Complex in San Francisco Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

UK-US trade deal could come into effect in ‘a couple of weeks', Starmer says
UK-US trade deal could come into effect in ‘a couple of weeks', Starmer says

Yahoo

time32 minutes ago

  • Yahoo

UK-US trade deal could come into effect in ‘a couple of weeks', Starmer says

Keir Starmer has said he hopes a trade deal struck last month with the US could come into effect 'in just a couple of weeks', as the White House has signalled that the UK will be spared the 50% steel and aluminium tariffs that came into force on Wednesday. Donald Trump said he had decided to 'provide different treatment' to the UK, after the deal was agreed between Washington and London – though it is yet to be signed. Starmer said in the House of Commons on Wednesday that the deal would be implemented 'within a very short time'. The executive order signed by the US president on Tuesday evening will raise import taxes for US companies buying from other countries. Levies will remain at 25% for imports from Britain, although the higher 50% could come in 'on or after 9 July' if the US administration 'determines that the UK has not complied with relevant aspects' of the deal. Challenged over the uncertainty during prime minister's questions by the Conservative leader, Kemi Badenoch, Starmer said: 'We are the only country in the world that isn't paying the 50% tax on steel and that will be coming down. We are working on it, to bring it down to zero; that is going to happen.' The business secretary, Jonathan Reynolds, said on Wednesday that 'essential steps' were taking place 'at pace' to turn Starmer's agreement with Trump into an implementable deal that would eliminate tariffs on steel and cars. Reynolds was speaking at a brief press conference in Brussels, announcing 13 partnerships with third countries to develop critical minerals supplies, including one pact to financially support Tungsten West, which hopes to reopen a closed mine in Devon. His visit to Brussels came a day after a meeting with the White House trade representative, Jamieson Greer, on the sidelines of an OECD summit in Paris. 'The two essential steps we are continuing to progress at pace is, first of all, the implementation of the agreement we have on sectoral tariffs. Steel and aluminium is part of that, alongside automotive, aerospace and the other critical sectors,' Reynolds said. 'We've had the decision not to extend 50% but we need to bring that 25% down to effectively zero … that is one piece of work which we continue to progress at pace.' Reynolds added that 'deeper negotiation about reciprocal tariffs' between the UK and the US was 'ongoing'. 'We don't want to see additional barriers to trade being put in place, and we continue to work constructively with all partners to secure that,' he said. The reduction in tariff rates for UK steelmakers was 'in the short-term … good news' said Rowan Crozier, the chief executive of Brandauer, a metal-stamping specialist. However, the boss of the Birmingham-based company told BBC Radio 4's Today programme that continual changes to tariff policy were damaging and creating uncertainty for business. 'It is quite far-reaching because essentially our customers are less confident in forward planning or ordering what they need,' Crozier said. He added that the company was having to contact its US customers directly, and called on the UK government to finalise the trade deal with the US in the coming weeks. 'I think the government have done well to keep us out of it for now but there is a definite deadline they have got to work to now to take away this uncertainty and get those tariffs to zero,' Crozier said. The industry body UK Steel welcomed Trump's decision to keep tariffs at 25% but said uncertainty remained over the final rate. Its director general, Gareth Stace, said: 'Continued 25% tariffs will benefit shipments already on the water that we were concerned would fall under a tax hike.' However, he added: 'We need the UK government to apply rocket boosters to those negotiations with the US administration to get that deal over the line and remove tariffs altogether on our imports and exports to the US market, which is our second-biggest export market.' Steel companies had been considering whether to turn shipments around in the mid-Atlantic to try to sell products in Europe rather than pay 50% tariffs. There were also questions over whether products immediately shipped back from the US would be liable to the levies. Liam Bates, the president for long products at Marcegaglia Stainless Sheffield, told the Guardian that the UK industry was relieved. He said: 'Storm in a teacup springs to mind.' However, he added that 'this is still a wider issue as anything not exclusively UK is attracting 50%' tariffs. It also does require this 0% deal is now done.' Paul Nowak, the general secretary of the TUC, said the exemption 'takes us back from the brink and many workers will breathe easier as a result' amid fears that thousands of British jobs could be lost if the steel and aluminium tariffs came into full force.

Faraday X Holds Signing Ceremony with Initial B2B Partners, Reflecting Strong Support and Endorsement from U.S. Dealers and Multi-Channel Network Companies
Faraday X Holds Signing Ceremony with Initial B2B Partners, Reflecting Strong Support and Endorsement from U.S. Dealers and Multi-Channel Network Companies

Yahoo

timean hour ago

  • Yahoo

Faraday X Holds Signing Ceremony with Initial B2B Partners, Reflecting Strong Support and Endorsement from U.S. Dealers and Multi-Channel Network Companies

Representatives of FX's first group of B2B partners were present at the recent FFAI Stockholders' Day, where they voiced their strong confidence and support for the Company and its Global Automotive Bridge Strategy. LOS ANGELES, June 05, 2025--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, announced a significant advancement in its FX brand's B2B sales strategy during its FFAI Stockholders' Day on May 31. This included a formal signing ceremony with new B2B partners, marking another breakthrough in the Company's innovative co-creation sales model in collaboration with leading influencer marketing agencies (known as multi-channel network companies, or MCNs). The event spotlighted remarks from FX's first group of B2B partners, including JC Auto, Skyhorse Auto, New PBB Auto, CreatoRev Agency and Good Deal World. The Company announced that it had signed binding deposit agreements totaling 600 FX Super One units with two U.S.-based influencer marketing agencies: CreatoRev Agency and Good Deal World, each of whom will also collaborate as paid co-creation partners, promoting the first-class AI-MPV experience through their signed influencers. These agreements bring total B2B binding deposits for the FX Super One to coverage of over 2,500 non-binding pre-orders, signaling strong demand for the Company's planned First Class AI-MPV, the Super One. This co-creation model with influencer marketing agency-affiliated content creators represents a world-first for the global auto industry: an end-to-end B2B2C co-creation ecosystem between an automaker and digital creators. It moves beyond traditional influencer marketing to a full-stack business model in the FX Co-Creation Ecosystem Online Direct Sales model. FX's B2B pre-orders span three major verticals: the FF Par (Partner) Program; commercial rental and livery fleet companies; and livestream ecommerce influencer marketing agencies. This B2B strategy forms the cornerstone of FX's rollout. In its first phase, Faraday Future plans to expand FX distribution across eight strategic states: California, New York, Florida, Texas, Washington, New Jersey, Nevada, and Massachusetts. "I am extremely confident in this new FX product," said Leo Li, President of New PBB Auto. "That's why I am willing to pay for a good product." "The B2B business is not only a critical starting point for our sales, but also a strategic pillar of FX expansion and our advancement of Global Automotive Bridge Strategy," said YT Jia, FF founder and Global Co-CEO of Faraday Future. "With this level of B2B engagement, we are already making meaningful progress toward our goal of disrupting the market dominance of established vehicles such as the Cadillac Escalade." ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes "forward looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding the Super One MPV, the FX brand, the reservations by JC Auto, Skyhorse Auto, New PBB Auto, CreatoRev and Good Deal World, and FX's geographic expansion plans, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: the ability of JC Auto, Skyhorse Auto, and New PBB Auto to successfully establish a premium fleet; the number of vehicles that each of them, as well as CreatoRev and Good Deal World, ultimately chooses to purchase, which may be as few as one or two; the ability of these organizations to identify purchasers for the Super One; the Company's ability to secure the necessary funding to execute on its AI, EREV and Faraday X (FX) strategies, each of which will be substantial; the Company's ability to design and develop EREV technology; the Company's ability to design and develop AI-based solutions; competition in the AI and EREV areas, where actual or potential competitors have or are likely to have substantial advantages relative to the Company, including but not limited to experience, expertise, funding, infrastructure and personnel; the ability of the Company to execute across multiple concurrent strategies, including the UAE, bridge strategy, or FX, EREV, AI, and US geographic expansion; the Company's ability to secure necessary agreements to license third-party range extender technology and/or license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; and the Company's ability to secure necessary permits at its Hanford, CA production facility; the potential impact of tariff policy; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to cover future warranty claims; the Company's ability to use its "at-the-market" program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC. View source version on Contacts Investors (English): ir@ Investors (Chinese): cn-ir@ Media: Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store